Skip to main content

Table 1 Baseline characteristics of patients (n = 201)

From: Baseline characteristics associated with NEDA-3 status in fingolimod-treated patients with relapsing-remitting multiple sclerosis

  Whole sample Tretament-naive Switchers for failure Switchers for safety  
N 201 24 117 60  
Gender, n (%)
 Female 141 (70) 17 (71) 88 (75) 36 (60)  
 Male 60 (30) 7 (29) 29 (25) 24 (40)  
Age, years
 mean (SD) 37.9 (9.3) 37.2 (8.0) 37.5 (9.9) 39.0 (8.5)  
 median [range] 38 [18–60] 37 [20–53] 38 [18–60] 39 [18–60]  
Time since first symptom, years *
 mean (SD) 8.8 (6.0) 5.1 (5.8) 8.2 (5.8) 11.3 (5.6)  
 median [range] 8 [<1–23] 2 [<1–18] 7 [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21] 11 [2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23]  
EDSS score      *
 mean (SD) 2.7 (1.4) 2.5 (1.0) 2.4 (1.3) 3.4 (1.5)  
 median [range] 2.0 [0–6.5] 2.0 [0–5.0] 2.0 [1.0–5.5] 3.5 [1.0–6.5]  
No. of relapses in previous year *
 mean (SD) 1.1 (0.6) 1.3 (0.5) 1.2 (0.4) 0.9 (0.8)  
 median [range] 1 [0–3] 1 [1, 2] 1 [1,2,3] 1 [0-3]  
Presence of gadolinium-enhancing lesions, n (%) 125 (62) 17 (71) 78 (67) 30 (50)  
  1. *p < 0.01 by the Kruskal-Wallis test